BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,261,473 | -17.0% | 18,532 | -0.5% | 0.15% | -24.6% |
| Q2 2023 | $1,519,869 | +8.1% | 18,619 | -1.7% | 0.20% | +0.5% |
| Q1 2023 | $1,405,456 | +96828.0% | 18,944 | +8.3% | 0.19% | -9.3% |
| Q4 2022 | $1,450 | -99.9% | 17,500 | +298.6% | 0.21% | +16.3% |
| Q3 2022 | $1,247,000 | -18.2% | 4,390 | -0.1% | 0.18% | -25.8% |
| Q2 2022 | $1,524,000 | -20.5% | 4,395 | -0.7% | 0.25% | -9.2% |
| Q1 2022 | $1,916,000 | -16.5% | 4,425 | -0.2% | 0.27% | -13.3% |
| Q4 2021 | $2,295,000 | +6.3% | 4,435 | -0.4% | 0.32% | -3.4% |
| Q3 2021 | $2,159,000 | +5.5% | 4,455 | -2.0% | 0.33% | +5.2% |
| Q2 2021 | $2,046,000 | +17.9% | 4,545 | 0.0% | 0.31% | +9.9% |
| Q1 2021 | $1,736,000 | +19.6% | 4,545 | -0.5% | 0.28% | +11.0% |
| Q4 2020 | $1,451,000 | +28.2% | 4,568 | 0.0% | 0.25% | +14.9% |
| Q3 2020 | $1,132,000 | -7.3% | 4,568 | -1.2% | 0.22% | -14.3% |
| Q2 2020 | $1,221,000 | +450.0% | 4,623 | +294.1% | 0.26% | +296.9% |
| Q1 2020 | $222,000 | -15.6% | 1,173 | -1.9% | 0.06% | +4.8% |
| Q4 2019 | $263,000 | +12.4% | 1,196 | 0.0% | 0.06% | +5.1% |
| Q3 2019 | $234,000 | -6.0% | 1,196 | 0.0% | 0.06% | -7.8% |
| Q2 2019 | $249,000 | +2.9% | 1,196 | -1.6% | 0.06% | -1.5% |
| Q1 2019 | $242,000 | – | 1,216 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |